Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial

Coronavirus Variant Immunologic Landscape Trial (COVAIL) Study Team

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

For COVAIL recipients of a coronavirus disease 2019 (COVID-19) Sanofi booster vaccine, neutralizing antibody titers were assessed as a correlate of risk (CoR) of COVID-19. Peak and exposure-proximal titers were inverse CoRs with covariate-adjusted hazard ratios (95% confidence intervals) 0.30 (0.11, 0.78) and 0.25 (0.07, 0.85) per 10-fold increase in weighted average titer.

Original languageEnglish (US)
Pages (from-to)223-227
Number of pages5
JournalClinical Infectious Diseases
Volume80
Issue number1
DOIs
StatePublished - Jan 15 2025

Keywords

  • correlate of risk
  • COVID-19 booster
  • exposure-proximal titer
  • Omicron
  • variant vaccine booster

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial'. Together they form a unique fingerprint.

Cite this